The 5 most recent market catalysts affecting $BHC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 65
Bausch Health Announces SILIQ Now Listed Under Alberta's Public Drug Plan For Eligible Moderate To Severe Plaque Psoriasis Patients
The listing of SILIQ under Alberta's public drug plan provides Bausch Health (BHC) with increased market penetration and potential revenue growth for this specific product within C…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch Health Companies Raises FY2026 Sales Guidance from $10.670B-$10.920B to $10.790B-$11.040B vs $10.773B Est
Bausch Health Companies (BHC) has raised its FY2026 sales outlook from a range of $10.670 billion-$10.920 billion to $10.790 billion-$11.040 billion, surpassing the analyst estimat…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 85
Bausch Health Companies Q2 Adj. EPS $1.26 Beats $1.04 Estimate, Sales $2.852B Beat $2.661B Estimate
This headline is a significant corporate catalyst for Bausch Health (BHC). The substantial beat on both adjusted EPS and sales indicates strong underlying business performance, pot…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 92
Bausch Health Companies Q2 Adj. EPS $1.26 Beats $1.06 Estimate, Sales $2.852B Beat $2.679B Estimate
Bausch Health Companies announced Q2 adjusted EPS of $1.26, surpassing the consensus estimate of $1.06 by 17.76%, and sales of $2.852 billion, beating the $2.679 billion estimate b…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 65
Bausch Health's Bausch Health, Canada Announces PrELIDEL Cream Listed Under Alberta's Public Drug Plan
The listing of PrELIDEL Cream under Alberta's public drug plan is a direct positive for Bausch Health, as it broadens the availability and affordability of their product within a k…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.